Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
Fuji
Argus Health
Cipla
Fish and Richardson

Generated: July 22, 2019

DrugPatentWatch Database Preview

Patent: 8,703,801

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,703,801
Title:Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications
Abstract: New chiral and achiral oxy-substituted cyclopentyl pyridinone diketocarboxamides and their derivatives and methods for their preparations are disclosed. The compounds include tautomers, regioisomers and geometric isomers. These complex carboxamides are designed as inhibitors of HIV replication through inhibition of HIV integrase. The compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents, especially other anti-HIV compounds (including other anti-HIV integrase agents), which can be used to create combination anti-HIV cocktails. Methods of treating AIDS and ARC and methods of treating or preventing infection by HIV are also described.
Inventor(s): Nair; Vasu (Athens, GA), Okello; Maurice O. (Athens, GA), Nishonov; Abdumalik A. (Boulder, CO), Mishra; Sanjaykumar (Pune, IN)
Assignee: University of Georgia Research Foundation, Inc. (Athens, GA)
Application Number:13/513,448
Patent Claims:see list of patent claims

Details for Patent 8,703,801

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Chiron PROLEUKIN aldesleukin VIAL 103293 001 1992-05-05 ➤ Try a Free Trial University of Georgia Research Foundation, Inc. (Athens, GA) ➤ Try a Free Trial RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 007 1989-06-01 ➤ Try a Free Trial University of Georgia Research Foundation, Inc. (Athens, GA) ➤ Try a Free Trial RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 006 1989-06-01 ➤ Try a Free Trial University of Georgia Research Foundation, Inc. (Athens, GA) ➤ Try a Free Trial RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 005 1989-06-01 ➤ Try a Free Trial University of Georgia Research Foundation, Inc. (Athens, GA) ➤ Try a Free Trial RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Chinese Patent Office
Covington
McKinsey
US Department of Justice
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.